Ninlaro (ixazomib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Ninlaro (ixazomib)

How to buy Ninlaro: You can order Ninlaro (ixazomib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Takeda Pharmaceuticals
Disease Blood Cancer
Indication Multiple Myeloma
Mode of Action Proteasome inhibitor (chemotherapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 1072833-77-2
HS Code 29319080
Strength 4 mg, 2.3 mg, 3 mg

Who is ixazomib for?

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy [1][3][6].

Recommended dose

Complete information about ixazomib dosage and administration can be found here [1][4].
The standard dosage is:
  • 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle
  • Dose should be taken at least one hour before or at least two hours after food
  • The dose may be reduced to 3 mg and to 2.3 mg in patients with moderately or severely reduced liver function and patients with severely reduced kidney function
Consult your treating doctor for personalised dosing.

What is ixazomib and how does it work?

Ixazomib is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Ixazomib targets and reversibly inhibits the proteasome enzyme complex within the cell. Proteasome is part of the cellular machinery, and among its functions, it regulates cellular division and survival. By interfering with proteasome’s function, ixazomib can lead to apoptosis (cell death) [2].
Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines [1].

What is ixazomib's approval status?

Ixazomib was approved by the Food and Drug Administration (FDA) in the United States on September 20, 2015, for the treatment of patients with multiple myeloma who have received at least one prior therapy [1]. On November 15, 2016, the TGA approved ixazomib [6]. The EMA approved ixazomib on November 24, 2016 [5].
The approval was based on an improvement in progression-free survival (PFS) in a multicentre, randomised, double-blind, placebo-controlled trial enrolling 722 patients with multiple myeloma who had received 1 to 3 prior lines of therapy. Patients were randomised in a 1:1 ratio to receive either a combination of ixazomib, lenalidomide and dexamethasone (n = 360) or the combination of placebo, lenalidomide and dexamethasone (n = 362). Patients continued treatment until disease progression or unacceptable toxicity. The trial showed a statistically significant improvement in PFS. The median PFS on the combination arm of ixazomib, lenalidomide and dexamethasone was 20.6 months (95 % CI: 17.0, NE) compared to a median PFS of 14.7 months (95 % CI: 12.9, 17.6) on the combination arm of placebo, lenalidomide and dexamethasone (PFS HR 0.74, 95 % CI: 0.59, 0.94; p value=0.012) [4].
The more common (>20 %) adverse reactions associated with an increased rate on the ixazomib combination arm compared to the placebo combination arm were: diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, and back pain [4].
[1] Summary of Product Characteristics: Ninlaro (ixazomib), Takeda Pharmaceuticals America, Inc., FDA, Nov. 2015.
[2] FDA archive. Ixazomib, 20/11/2015, cited on 24/08/2016.
[3] EMA. Human Medicines: Ninlaro (ixazomib), 7/12/2016, cited on 18/04/2017.
[4] Summary of Product Characteristics: Ninlaro (ixazomib), Takeda Pharmaceuticals, EMA, Nov. 2016.
[5] Takeda Press Release. Ninlaro (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma, 24/11/2016.
[6] TGA Public Summary. Ninlaro (ixazomib), 15/11/2016.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.